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Crystallisation and structure of BRD4(1) in complex with 13 
E.coli expressed BRD4-(42-169) at a concentration of 10mg/ml was mixed with 13 to a final 
concentration of 400 µM, 2% DMSO and incubated on ice for 1 hour.  Note that due to limited solubility 
and DMSO tolerance, a molar excess of the compound concentration could not be attained.  Low 
volume sitting drop crystallisation was performed in MRC 2 well plates using a ratio of 2:1 protein : 
mother liquor and crystals formed in a condition containing 0.2M K3Citrate and 10% PEG 10k (w/v) at 
4 °C.  Crystals were cryoprotected in mother liquor supplemented with a further 20% glycerol.  
Diffraction data was collected on beamline IMCA-CAT 17-ID at the Advanced Photon Source, 
Argonne, IL, USA using a  Dectris Pilatus 6M detector and processed using XDS [Kabsch, W. Acta 
Cryst. D66, 125-132 (2010)].  Molecular replacement solution was determined with 2OSS.pdb using 
Phaser [McCoy, A.J. et al. J. Appl. Cryst. 40, 658-674 (2007)].  The P212121 cell (α=β=γ=90°, 
a=41.754Å, b=59.769Å, c=107.151Å) has a dimer in the ASU.  Model building was performed using 
Coot [Emsley, P. et al. Acta Cryst. D66, 486-501 (2010)] and refined using Buster [Bricogne, G. et al. 
Buster version 2.11.6. Cambridge, United Kingdom: Global Phasing Ltd. (2011)].  13 could easily be 
modelled into the difference density using ligand restraints generated by Grade [Smart, O.S. et al. Grade 
version 1.2.9. Cambridge, United Kingdom: Global Phasing Ltd. (2011)].  It should be noted that the 
electron density for the ligand was of sufficient quality to enable it to be built in two alternate and 
equivalent conformations with a total final occupancy of 1.0. The statistics for the data collection and 
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refined co-ordinates are given in (Table S1).  The final model has been deposited in the protein databank 
under accession code 5KHM. 
Table S1 - X-ray data collection and refinement statistics for BRD4(1) in complex with 13. 
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  5KHM (13) 
Data collection  
Space group P212121 
Cell dimensions  
    a, b, c (Å) 41.75, 59.77, 107.15 
Α, β, γ (°)  90, 90, 90 
Resolution (Å) 53.58 – 1.48 (1.52-1.48) * 
Rsym or Rmerge 0.064 (0.918) 
I / σI 18.1 (2.5) 
Completeness (%) 100 (100) 
Redundancy 7.8 (8.0) 
  
Refinement  
Resolution (Å) 53.58 – 1.48 
No. reflections 45557 
Rwork / Rfree 17.9/ 21.0 
No. atoms  
    Protein 2125 
    Ligand/ion 35 
    Water 282 
B-factors  
    Protein 23.0 
    Ligand/ion 18.2 
    Water 33.4 
R.m.s. deviations  
    Bond lengths (Å) 0.98 
    Bond angles (°) 0.01 
*All structures solved using data from a single crystal. *Values in parentheses are for highest-resolution 
shell. 
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Correlations of potency values between BRD4 FP potency, ER downregulation, c-Myc 
downregulation and growth inhibition. 
Table S2 - Correlation coefficients (r2) between the potency values 
 
Scatterplot matrix 
 
Further discussion 
The different cellular context for these cell based readouts needs to be considered. In the end they all 
serve as surrogate assays for cellular level bromodomain target-engagement (TE) so it is not 
surprising that these assays correlate for BET inhibitors.  
cMyc DR assay was done in multiple myeloma cell line MM1.s. BRD4 controlling Myc expression in 
MM1.S in bromodomain-dependent manner is well established.  Cellular cMyc down-regulation is 
frequently used to assess BET inhibitor activity in literature.  
Our ER DR assay was carried out in MCF7 ER+ breast cancer cell line.  BRD4/BRD3 has been 
shown to be crucial for recruiting WHSC1 to promote ESR1 transcription, again in a bromodomain-
BR4 FP pKi ERDR pIC50 cMyc DR pIC50 MM1S pGI50
BRD4 FP pKi 0.80 0.78 0.49
ERDR pIC50 0.80 0.88 0.60
cMyc DR pIC50 0.78 0.88 0.85
MM1S pGI50 0.49 0.60 0.85
S6 
 
dependent manner (Cell Res. 2014, 24, 809-819). Thus ER down-regulation may be used to measure 
BET inhibitor activity and our correlation data enhances this notion.  
BRD4 and AR linkage has also been established (Nature, 2014, 510, 278-82). BRD4 binds directly to 
the acetylated AR via its bromodomains, and BRD4 co-localizes with AR to AR target loci to 
function as a co-regulator of AR-mediated gene transcription. We believe our AR DR assay measures 
the nuclear AR level and this readout correlates very well with more established Myc DR assay 
towards our BET inhibitors and also others such as JQ1 and I-BET762. 
Alexa647-labelled probe 
 
2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-
yl)acetic acid (2, 8.0 mg, 0.02 mmol) and tert-butyl(3-aminopropyl)carbamate (3.5 µL, 0.020 mmol) 
were dissolved in DMF (1.0 mL), then TEA (7.0 µl, 0.050 mmol) was added to give a yellow 
solution. EDC (4.6 mg, 0.020 mmol) and HOBT (3.7 mg, 0.020 mmol) were added. The reaction was 
stirred for 16 hours. The reaction was partitioned between EtOAc (10 mL) and satd. NaHCO3 (10 
mL). The organic layer was extracted, washed with brine, dried over Na2SO4 and stripped to dryness 
giving crude intermediate tert-butyl (3-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propyl)carbamate (6.0 mg, 54%).  A sample of 
the intermediate (3.4 mg, 6.10 µmol) was dissolved in DCM (1.0 mL). Trifluoroacetic acid (0.10 mL, 
1.3 mmol) was added and stirred for 2 hours. The reaction was stripped to dryness and redissolved in 
DMSO (1 mL). TEA (4.25 µl, 0.03 mmol) was added, followed by 2-((1E,3E,5E)-5-(3,3-dimethyl-5-
sulfo-1-(3-sulfopropyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-
oxohexyl)-3-methyl-5-sulfo-1-(3-sulfopropyl)-3H-indol-1-ium (5.8 mg, 6.1 µmol). The reaction was 
stirred for 16 hours. The mixture was purified directly by preperative HPLC, eluting with 0-50% 
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MeCN in water (NH3 modifier). This delivered the desired product 3-(6-((3-(2-((6S)-4-(4-
chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-
yl)acetamido)propyl)amino)-6-oxohexyl)-2-((1E,3E,5E)-5-(3,3-dimethyl-5-sulfo-1-(3-
sulfopropyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3-methyl-5-sulfo-1-(3-sulfopropyl)-3H-indol-1-
ium (2.5 mg, 32%) as a blue gum.  
1H NMR (300 MHz, CD3OD) δ 0.6 (br s, 1H), 0.9 (br d, J = 5.5 Hz, 2H), 1.2 - 1.3 (m, 3H), 1.3 (t, J = 
7.3 Hz, 6H), 1.4 - 1.5 (m, 2H), 1.6 - 1.8 (m, 13H), 2.0 (t, J = 7.3 Hz, 2H), 2.2 (br d, J = 11.3 Hz, 5H), 
2.4 (s, 3H), 2.7 (d, J = 1.3 Hz, 3H), 2.9 - 3.0 (m, 4H), 3.1 - 3.3 (m, 6H), 3.3 - 3.4 (m, 1H), 4.3 (br s, 
4H), 4.6 (dd, J = 8.7, 5.7 Hz, 1H), 6.5 (br d, J = 13.6 Hz, 2H), 6.7 (br t, J  =12.8 Hz, 1H), 7.3 - 7.5 (m, 
6H), 7.8 - 7.9 (m, 4H), 8.2 - 8.4 (m, 2H). Purity 94% by LC-MS, m/z: ES+ [M+H]+ 1297.3 
 
 
